Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Datteln – page 35

1 785 clinical trials in Datteln, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Datteln at a glance
1 785
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 785 trials in Datteln

Open in trial search

Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:Institut Gustave Roussy

Bladder cancer

Recruiting

Study of mRNA-4157 and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Chondropathy

Recruiting

Study of BP CC 001 stem cells from umbilical cord tissue for treating knee cartilage damage

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:BP CC 001
  • Sponsor:BIONCaRT GmbH

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Technische Universitat Dresden

Study on the Effects of TRI-001 for Patients with Chronic Limb Threatening Ischemia Due to Peripheral Arterial Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic regulatory macrophages
  • Sponsor:Ferring Ventures GmbH

Breast cancer

Recruiting

Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inavolisib
  • Sponsor:F. Hoffmann-La Roche AG

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effects of NSC001 and Trospium Chloride for Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NGX-267
  • Sponsor:Nsc Therapeutics GmbH

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Datteln

What the registry says about research in the country

01 Pediatric Oncology

Innovative research focusing on lymphoma and leukemia treatments in children and adolescents, including studies on B-cell lymphomas and acute myeloid leukemia. These trials aim to improve survival rates through targeted therapies and novel treatment combinations.

  • B-cell lymphoma treatments
  • Acute lymphoblastic leukemia
  • Germ cell tumors

Advanced protocols incorporating immunotherapy and chemotherapy combinations are being evaluated for optimal treatment outcomes.

02 Neurological Conditions

Studies addressing various neurological disorders, including multiple sclerosis and rare conditions like tuberous sclerosis complex. Research focuses on testing new therapeutic approaches and evaluating long-term neuropsychological outcomes.

  • Relapsing-remitting MS
  • Myelin disorders
  • Developmental disorders

Trials emphasize early intervention strategies and comparative treatment effectiveness.

03 Neonatal Care

Critical research in preterm infant care, focusing on respiratory distress syndrome and retinopathy of prematurity. Studies evaluate new treatment approaches and preventive measures for improved outcomes.

  • Surfactant administration
  • Retinopathy prevention
  • Respiratory support

Investigations aim to establish optimal protocols for premature infant care and development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.